Company Overview of Ambit Biosciences Corporation
Ambit Biosciences Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. The company’s products include quizartinib, an orally administered FMS-like tyrosine kinase 3 inhibitor that has completed Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia. Its drug candidates also comprise AC410, a small molecule inhibitor of Janus kinase 2, which is in Phase 1 clinical trials; and AC708, a receptor tyrosine kinase inhibitor that is in pre-clinical studies for the treatment of oncology, autoimmune, and i...
11080 Roselle Street
San Diego, CA 92121
Founded in 2000
Key Executives for Ambit Biosciences Corporation
Chief Executive Officer and President
Co-Founder, Chairman of Scientific Advisory Board
Chief Financial Officer and Principal Accounting Officer
General Counsel and Senior Vice President
Compensation as of Fiscal Year 2014.
Ambit Biosciences Corporation Key Developments
Ambit Biosciences Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015
Jan 28 15
Ambit Biosciences Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Presentation Date & Speakers: Feb-25-2015, Alan Fuhrman, Chief Financial Officer and Principal Accounting Officer. Feb-26-2015, Michael A. Martino, Chief Executive Officer and President.
Ambit Biosciences Corporation Announces Executive Resignations
Nov 17 14
Ambit Biosciences Corporation announced resignation of David Bonita, Faheem Hasnain, Jeffrey S. Hatfield, Standish M. Fleming, Mark G. Foletta, Allan P. Marchington, Michael A. Martino, David Parkinson and Isai Peimer as a Board of Directors and any committees thereof, of Ambit.
Ambit Biosciences Corporation(NasdaqGM:AMBI) dropped from NASDAQ Composite Index
Nov 11 14
Ambit Biosciences Corporation will be removed from the NASDAQ Composite Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 28, 2014